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Bone marrow transplantation offers great promise for treating a number of disease states. 
However, the widespread application of this approach is dependent upon the development of 
less toxic methods to establish chimerism and avoid graft-versus-host disease (GVHD). 
CD8
 
 
 
/TCR
 
 
 
 facilitating cells (FCs) have been shown to enhance engraftment of hematopoietic 
stem cells (HSCs) in allogeneic recipients without causing GVHD. In the present studies, 
we have identified the main subpopulation of FCs as plasmacytoid precursor dendritic cells 
(p-preDCs). FCs and p-preDCs share many phenotypic, morphological, and functional features: 
both produce IFN-
 
 
 
 and TNF-
 
 
 
, both are activated by toll-like receptor (TLR)-9 ligand (CpG 
ODN) stimulation, and both expand and mature after Flt3 ligand (FL) treatment. FL-mobilized 
FCs, most of which express a preDC phenotype, significantly enhance engraftment of HSCs 
and induce donor-specific tolerance to skin allografts. However, p-preDCs alone or p-preDCs 
from the FC population facilitate HSC engraftment less efficiently than total FCs. Moreover, 
FCs depleted of preDCs completely fail to facilitate HSC engraftment. These results are the 
first to define a direct functional role for p-preDCs in HSC engraftment, and also suggest 
that p-preDCs need to be in a certain state of maturation/activation to be fully functional.
 
An elusive goal in organ transplantation and
the treatment of autoimmune diseases is the
induction of tolerance. BM chimerism induces
robust donor-specific tolerance to organ and
cellular transplants and, as such, offers signifi-
cant therapeutic potential (1, 2). However,
graft-versus-host disease (GVHD) and the tox-
icity of ablative conditioning have limited the
widespread clinical application of this approach
(3, 4). T cell depletion (TCD) of BM prevents
GVHD, but is associated with significantly im-
paired engraftment (5–7). We were the first to
identify a CD8
 
 
 
/TCR
 
 
 
 BM population that
facilitates hematopoietic stem cell (HSC) engraft-
ment  across MHC barriers without causing
GVHD (8–10). CD8
 
 
 
/TCR
 
 
 
 facilitating cells
(FCs) are comprised of a heterogeneous popu-
lation and share cell surface markers with T
cells, but are distinct from them (11). FCs also
share phenotypic characteristics with CD8
 
 
 
lymphoid DCs (8).
The therapeutic potential of DCs in trans-
plantation has recently become the focus of in-
tense research, with the emerging concept of
using “tolerogenic” DCs in the graft to silence
host immunity and enhance engraftment, while
also preventing GVHD (12–16). Besides their
well-characterized immunogenic function, DCs
have been demonstrated to play a role in the
induction of tolerance by tolerizing donor T
cells to self-antigen (17, 18). The dual func-
tions of DCs (immunization versus tolerization)
can be explained by: (a) the recent identification
of distinct DC subsets; (b) the dose, nature, and
duration of activation signals received by the
DCs; and (c) the maturational state of DCs
upon encounter with antigen (15, 19).
The recently defined DC subpopulation of
plasmacytoid precursors DCs (p-preDCs) has
become a major focus of interest in transplanta-
tion. Recent findings suggested that p-preDCs
are tolerogenic DCs because the presence of
these cells in the BM graft correlated with a
decreased occurrence of GVHD (20–22). Ini-
tially, p-preDCs were described as the major
 
I.J. Fugier-Vivier and F. Rezzoug contributed equally to this
work.
 
CORRESPONDENCE
Suzanne T. Ildstad: 
suzanne.ildstad@louisville.edu
 
Abbreviations used: CM, chi-
mera media; CSM, cell sort me-
dia; FC, facilitating cell; FL, Flt3 
ligand; GVHD, graft-versus-host 
disease; HSC, hematopoietic 
stem cell; MST, median survival 
time; p-preDC, plasmacytoid 
precursor DC; TBI, total body 
irradiation; TCD, T cell deple-
tion; TLR, toll-like receptor. 
P
 
-
 
PRE
 
DC
 
S
 
 FACILITATE ALLOGENEIC HSC ENGRAFTMENT | Fugier-Vivier et al.
 
374
 
type 1 IFN-producing cells due to their potent capacity to
produce IFN-
 
 
 
 in response to virus or microbial stimulation
with toll-like receptor (TLR)-9 ligands such as CpG ODN
(23–27). The phenotype of murine p-preDCs has now been
characterized as a B220
 
 
 
/CD11c
 
dim
 
/CD11b
 
 
 
 cell popula-
tion with a plasmacytoid morphology (24, 28). p-preDCs
can induce the development of either a Th1 or a Th2 im-
mune response, depending on the dose and/or the nature of
antigen exposure (19). In HSC transplantation, a direct func-
tional role for p-preDCs has not yet been defined.
In the present studies, we report that the majority of FCs
share functional characteristics with p-preDCs in their ability
to secrete IFN-
 
 
 
, TNF-
 
 
 
, and other cytokines and mature
by up-regulating activation markers, after activation by CpG
ODN. Flt3 ligand (FL), a key cytokine for p-preDC devel-
opment (25, 28, 29), similarly regulates FCs in that FCs can
be generated from FL-supplemented BM cell cultures, as
well as expanded and mobilized in vivo in FL-treated mice.
The majority of FL-mobilized FCs exhibit a p-preDC phe-
notype. Additionally, these mobilized FCs facilitate long-
term HSC engraftment and induce tolerance in allogeneic
recipient mice. Because of the similarities between p-preDCs
and FCs, we examined whether p-preDCs and p-preDCs
from the FC population contribute directly to HSC facilita-
tion in vivo. We show for the first time that p-preDCs sig-
nificantly facilitate HSC engraftment. However, facilitation
by the p-preDCs as well as preDC FCs is significantly less ef-
ficient than that for total FCs. Moreover, when p-preDCs
are depleted from the FC population, facilitation of HSCs is
lost. These data demonstrate that p-preDCs play a key role
in facilitation of HSCs by FCs and suggest that FCs consist of
p-preDCs that act in concert with other collaborative cell
types to allow optimal HSC engraftment. A clear definition
of FC phenotype and mechanism of action may provide a
promising cell-based approach to enhance engraftment and
tolerance while avoiding alloreactivity.
 
RESULTS
CD11c
 
 
 
 cells are the predominant cell type 
within the FC population
 
To better characterize FCs, we analyzed markers expressed
on the sorted CD8
 
 
 
 
 
/TCR
 
 
 
 FC population by FACS anal-
ysis. Approximately 65–70% of FCs express CD11c
 
 
 
 (Fig. 1
A), and 75–88% of FCs express B220 (Fig. 1 A). Among the
subpopulations negative for B220 expression, 4–6% were
NK (NK1.1
 
 
 
 and DX5
 
 
 
), 6–7% were granulocytes (Gr-1
 
 
 
),
and 2–4% were monocytes (CD14
 
 
 
; Fig. 1 A). Among the
B220
 
 
 
 subpopulation, only 15% were B cells (CD19
 
 
 
; Fig.
1 A), and 65% were DCs (CD11c
 
 
 
). The CD19
 
 
 
/B220
 
 
 
FC subpopulation was also positive for intracytoplasmic IgM
(unpublished data), confirming a B cell phenotype. Taken
together, these data demonstrate that there are distinct sub-
populations within the sorted FCs, with a majority as DCs.
In addition, the sorted FCs exhibited a heterogeneous mor-
Figure 1. CD8 /TCR  FCs: a heterogeneous population. (A) CD11c  
FCs are the predominant subpopulation in sorted FCs. BMCs stained with 
anti-  –TCR FITC, anti-  –TCR FITC, and anti-CD8 –PE were isolated from 
the lymphoid gate (intermediate forward scatter and lower side scatter, R1) 
and sorted for CD8  /TCR   /TCR    (FC gate). The sorted FCs were 
blocked using the anti-Fc receptor Ab and stained with anti-B220–PerCP 
and anti-Gr–1 FITC, or anti-B220–PerCP, anti-NK1.1 FITC and anti-DX5 FITC, 
or anti-B220–PerCP with anti-CD19 APC, or anti-B220–PerCP with anti-
CD11c APC, or anti-B220–PerCP with anti-CD14 FITC. Isotype-specific con-
trols were performed. Flow cytometric profiles are representative of at least 
three experiments in B6, two experiments in B10, and two experiments in 
B10.BR. The reanalysis of sorted FCs stained with different isotype Ab allowed 
us to verify the purity of the population ( 95%) and the absence of T cell 
contaminants ( 1%). Morphology of sorted CD8 /TCR  FCs was examined 
after (B) Wright-Giemsa staining with optical microscopy at two different 
magnifications and (C) by transmission electron microscopy. 
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phology on cytospins with Wright-Giemsa staining (Fig. 1
B) and by transmission electronic microscopy (Fig. 1 C).
 
95% of CD11c
 
 
 
 FCs resemble p-preDCs
 
Because CD11c
 
 
 
 DCs represent the largest subset in the FC,
we analyzed the known subtypes of DCs present in the
sorted FC population by FACS analysis (Fig. 2 A). Strik-
ingly, p-preDCs (B220
 
 
 
/CD11c
 
dim
 
/CD11b
 
 
 
) comprised
93–95% of the CD11c
 
 
 
 FC subpopulation (Fig. 2 A). To
confirm that the predominant CD11c
 
 
 
 FC subpopulation
was related phenotypically to p-preDCs, we analyzed the
presence of CD4 on sorted FCs, as at least 70% of BM
p-preDCs have been shown to express the CD4 antigen
(24). Approximately 40–50% of FCs expressed CD4 (Fig. 2
B), and this CD4
 
 
 
 FC subpopulation was almost exclusively
of plasmacytoid phenotype (CD11c
 
 
 
/B220
 
 
 
).
The majority of FCs exhibited a characteristic plasmacy-
toid morphology, with a round shape, a smooth surface, and
an eccentric nucleus after Wright-Giemsa staining (Fig. 2 C).
Transmission electronic microscopy confirmed the plasmacy-
toid morphology of FCs (Fig. 2 D). In the face of these strik-
ing phenotypic and morphological similarities, we hypothe-
size that the predominant CD11c
 
dim
 
/B220
 
 
 
/CD11b
 
 
 
 cell
population in the FC gate is likely the equivalent to CD8
 
 
 
 
 
p-preDCs, a small subpopulation of BM p-preDCs (24, 30).
 
FCs produce IFN-
 
 
 
, TNF-
 
 
 
, and other cytokines after CpG 
ODN stimulation
 
Given that IFN-
 
 
 
, TNF-
 
 
 
, and inflammatory cytokine
production are main features of p-preDCs, we examined
whether FCs resemble p-preDCs in response to stimulation
with CpG ODN. FCs produced IFN-
 
 
 
 at levels similar to
those produced by p-preDCs after CpG ODN stimulation
(Fig. 3 A). Additionally, as for preDCs, FCs did not produce
significant levels of IFN-
 
 
 
 after LPS stimulation (unpublished
data). In addition to IFN-
 
 
 
 secretion, FCs produce large
amounts of TNF-
 
 
 
 (Fig. 3 B) and other proinflammatory cy-
tokines including high amounts of MIP-1
 
 
 
/CCL3, moderate
amounts of IL-6 and RANTES/CCL5, and low levels of IL-
12p70 after CpG ODN stimulation (Fig. 3 C). FCs produced
low amounts of IL-9, IL-10, IFN-
 
 
 
, and MCP-1/CCL2
(Fig. 3 C) and no GM-CSF, IL-1
 
 
 
, IL-2, IL-4, IL-5, or IL-
13 (unpublished data) after culture with medium or CpG
stimulation. In total, these data demonstrate that FCs resem-
ble p-preDCs in response to CpG ODN.
Because p-preDCs mature after CpG ODN stimulation,
we analyzed whether FCs resemble p-preDCs in matura-
tion/activation (28, 30, 31). After overnight exposure with
medium or CpG ODN, FCs were analyzed for MHC-class
II, CD80, and CD86 expression (Fig. 3 D). Class II and
CD86 were highly up-regulated on FCs (from 18 
 
 
 
 8% to
74 
 
 
 
 6.5% and from up to 7 
 
 
 
 19% to 86 
 
 
 
 12%, respec-
tively, 
 
n
 
 
 
  
 
4), and, to a lesser extent, CD80 (from 10 
 
 
 
3.7% to 23.5 
 
 
 
 8%, 
 
n
 
 
 
  
 
4; Fig. 3 D). Similarly, CD86 is up-
regulated on p-preDCs (from 12 
 
 
 
 9% to 85 
 
 
 
 13%, 
 
n
 
 
 
  
 
2)
in a similar amount to FCs, but class II up-regulation on
p-preDCs (from 10 
 
 
 
 2% to 39 
 
 
 
 4%, 
 
n
 
 
 
  
 
2) did not in-
crease as much as it did on FCs. The increase of CD80 (from
7 
 
 
 
 1% to 12.5 
 
 
 
 1%, 
 
n
 
 
 
  
 
2) on p-preDCs was only slight.
 
FL is a key cytokine for FC expansion 
and maturation in vitro
 
Coculture of BMCs with FL increases the frequency of
p-preDCs (28, 29). We therefore determined whether FCs
can be propagated using similar culture conditions. After 10 d
in culture with FL, FCs (FL-derived FCs), and p-preDCs
(FL-derived p-preDCs) were sorted. We observed a seven-
fold increase in FL-derived FCs (
 
n
 
 
 
  
 
8) and 17
 
-
 
fold in FL-
derived p-preDCs (
 
n
 
 
 
  
 
4) from the cultured BM (Fig. 4 A).
Interestingly, FL-derived FCs were in a more activated
state than fresh FCs, as evidenced by their morphology (Fig.
4 B). Dendrites were already beginning to appear on FL-
derived FCs after overnight culture, and their appearance
was amplified after exposure to CpG ODN. FL-derived FCs
also produced significant amounts of IFN-
 
 
 
 after overnight
culture (Fig. 4 C), perhaps reflective of their activation state.
FL-derived p-preDCs also produced IFN-
 
 
 
 after overnight
culture. Stimulation with CpG ODN overnight further in-
creased the IFN-
 
 
 
 secretion, as well as TNF-  and IL-
12p70 production.
The effect of FL on FCs or p-preDCs was further evalu-
ated by analyzing activation marker expression after over-
Figure 2. CD11c  FCs resemble p-preDCs. (A) CD11c  FCs present a 
p-preDC phenotype. Sorted FCs were stained with anti-B220–PerCP, anti-
CD11c APC, and anti-CD11b FITC after FcR blocking. The CD11cdim popula-
tion (up to 70% of the total FC gate) was analyzed for B220 and CD11b 
expression. Flow cytometric profiles are representative of at least three 
separate experiments in both B6 and B10. (B) CD4 FCs present a p-preDC 
phenotype. Freshly sorted FCs from BM were stained with anti-CD11c 
FITC, anti-B220–PerCP, and anti-CD4 APC Ab after FcR blocking. The CD4  
population was analyzed for B220 and CD11b expression. Flow cytometric 
profiles are representative of at least two separate experiments in B6. 
Morphology of the majority of sorted CD8 /TCR  FCs was examined (C) 
after Wright-Giemsa staining under optical microscopy ( 100), and (D) by 
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night culture. Interestingly, both FL-derived FCs and FL-
derived p-preDCs significantly up-regulated expression of
MHC class II, CD80, and CD86, as compared with FCs and
p-preDCs sorted from fresh BM cells (BMCs; Fig. 4 D). In-
deed, 40% of FL-derived FCs expressed class II versus 18%
of fresh FCs, 47% expressed CD80 versus 11% of fresh FCs,
and 51% expressed CD86 versus 17% of fresh FCs. Similarly,
FL-derived p-preDCs up-regulated the level of class II,
CD80, and CD86. CpG ODN exposure overnight further
increased the level of expression of these activation markers
on both FL-derived FCs (73% of class II, 48% of CD80, and
77% expression of CD86) and FL-derived p-preDCs (88% of
class II, 63% of CD80, and 87% of CD86; Fig. 4 D).
In conclusion, FCs as well as p-preDCs expanded from
FL-supplemented BMC cultures are in a more advanced ac-
tivation state than freshly isolated cells. Nevertheless, they
display similar cytokine secretion and activation marker up-
regulation after exposure to CpG.
In vivo FL-mobilized FCs facilitate HSC engraftment in 
allogeneic recipients
FL treatment in vivo expands DCs, including the p-preDCs
subtype (25, 32). We showed previously that mice treated
with FL demonstrate a significant expansion of FCs in PB,
BM, and spleen, with the peak production at 10 d (33).
Here, we characterized the influence of FL administration
on the different subtypes in the FC population in PB and an-
alyzed the functional potential of purified blood FL-mobi-
lized FCs (FL-FCs) to facilitate HSC engraftment. Approxi-
mately 85–90% of FL-FCs in the PB express CD11c (Fig. 5
A), and 5–7% express NK1.1, but none express CD19 or
CD14 (unpublished data). Interestingly, there were clearly
two distinct DC populations: CD11cdim and CD11cbright.
Further analysis showed that the 60% CD11cdim population,
characteristic of an immature DC phenotype, was ex-
clusively the p-preDCs phenotype (B220 /CD11cdim/
CD11b ). The 20% CD11cbright population, characteristic of
mature DCs, contained a majority of mature lymphoid DCs
(B220 /CD11cbright/CD11b ), and all expressed the CD86
marker (unpublished data). Therefore, FL mobilization in-
duced a significant increase in the CD11c population, and
dramatically decreased the B cell and monocyte populations
(unpublished data).
We next asked whether purified FL-FCs from PB main-
tained their ability to facilitate HSC engraftment in alloge-
neic recipients. HSCs were sorted from the marrow of un-
treated B10.BR mice and FCs from the PB of FL-treated
B10.BR mice after 10 d of treatment. B10-recipient mice
were ablatively conditioned and reconstituted with 5,000
HSCs plus 30,000 FL-FCs. Control B10 mice received
5,000 HSCs alone or 5,000 HSCs plus 30,000 FCs from un-
treated B10.BR donor mice. FL-FCs were functional, as ev-
idenced by 87% long-term survival ( 180 d; Fig. 5 B). All
mice receiving FCs from untreated mice with HSCs sur-
vived longer than 180 d. In contrast, none of the mice re-
ceiving allogeneic HSCs alone survived   170 d. Thus, the
FL-FCs from PB exhibited significant facilitation of engraft-
ment of HSCs in allogeneic recipients.
Figure 3. FCs exhibit in vitro function similar to p-preDCs. (A) FCs 
secrete IFN- . BM FCs and p-preDCs were cultured with CpG ODN or medium 
only. Culture cell-free supernatants were collected after 12 or 24 h and 
IFN-  production was assessed by ELISA. Data are means   SEM of at 
least two experiments, run in duplicate. (B) FCs secrete TNF- . BM FCs and 
p-preDCs were cultured with medium only or CpG ODN. Culture cell-free 
supernatants were collected after 24 h and TNF-  was assessed by ELISA. 
Data are means   SEM of at least two experiments, run in duplicate. 
(C) FCs secrete other proinflammatory cytokines. BM FCs (0.05   106 cells/
well) were cultured with medium only or CpG ODN. Supernatants were 
collected after 18 h and MIP-1  (CCL3), MCP-1 (CCL2), RANTES (CCL5), 
IFN- , IL-6, IL-10, IL-12p70, and IL-9 were assessed by LINCOplex multi-
plex immunoassay. Data are means   SEM of three separate experiments, 
run in duplicate. (D) Up-regulation of activation markers on FCs. Sorted 
FCs and p-preDCs from BMCs were cultured with medium or CpG ODN for 
18 h and stained with the MHC–class II, CD80 or CD86 FITC labeled, or iso-
type control mAb. Data on expression of markers are representative of at 
least four experiments on FCs and three experiments on p-preDCs.JEM VOL. 201, February 7, 2005 377
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We examined recipients of HSCs plus FL-FCs for donor
chimerism and multiple hematopoietic lineages 3 mo after
transplantation. All surviving animals tested showed  95%
donor chimerism for multiple lineages, including T cells,
NK cells, B cells, macrophages, and granulocytes (Fig. 5 C).
To test whether these FL-FCs plus HSC chimeras were
functionally tolerant, skin grafts from B10.BR (HSC donor)
or BALB/c (third-party) mice were performed. Donor-spe-
cific skin grafts were accepted by the chimeras (median sur-
vival time [MST]  100 d), while third-party (BALB/c) grafts
were promptly rejected (MST   15 d; Fig. 5 D). In conclu-
sion, FL treatment significantly expands FCs in PB that consist
of 85–90% CD11c  cells, with 20% of these being mature
DCs, and the distinct majority (60–65%) resembling the
p-preDCs phenotype. Most importantly, FL-FCs enhance HSC
engraftment and tolerance induction in allogeneic recipients.
Purified p-preDCs facilitate HSC engraftment in allogeneic 
recipients with less efficiency than FCs
 Due to the predominance of p-preDCs in either fresh BM
FCs or FL-mobilized FCs, we directly addressed whether
purified p-preDCs from BMCs were functional to facilitate
HSC engraftment. 5,000 B6 HSCs were injected alone into
ablated C3H mice (HSC group), or with 30,000 B6 FCs
(HSCs   FCs group), or with 30,000 B6 p-preDCs (HSCs  
p-preDCs group). Engraftment was significantly enhanced
in recipients of HSCs   p-preDCs (51% survival, n   22)
compared with the HSC alone group (P   0.0076; Fig. 6
A). However, the survival was significantly enhanced in the
HSCs   FCs group (95% survival, n   21) compared with
the HSC alone group (P   0.00001) and was also signifi-
cantly enhanced over the HSCs   p-preDCs group (P  
0.0083). Thus, p-preDCs effectively facilitated HSC en-
Figure 4. FL is a key cytokine for FC expansion and maturation in 
vitro. (A) FCs expansion from FL-cultured BMCs. Fresh BMCs and BMCs 
cultured with FL for 10 d were sorted for CD8  /TCR   /TCR    FCs 
and CD11c /CD11b /B220  p-preDCs. The data shown represent the per-
centage of sorted cells in the lymphoid gate and are means   SEM of 
more than 8 experiments for FL-derived FCs and FL-derived p-preDCs and 
of more than 10 experiments for FCs and preDCs in fresh BM. (B) Mor-
phology of sorted FL-derived FCs after 18 h incubation. BM FCs were 
sorted from fresh BM or from a 10-d FL-cultured BM. Cells were incubated 
for 18 h with medium or CpG ODN and were examined after Wright-Giemsa 
staining by optical microscopy at several magnifications. Arrows indicate 
dendrites. (C) Cytokine secretion of FL-derived FCs. BM FCs and p-preDCs 
were sorted from a 10-d FL-cultured BM and were incubated with medium 
only or CpG ODN. Culture supernatants were collected after 24 h and TNF- , 
IFN- , and IL-12p70 were assessed by ELISA. Data are representative of at 
least two different experiments, run in duplicate. (D) Up-regulation of 
activation markers on FL-derived FCs. FL-derived FCs and FL-derived 
p-preDCs were sorted from a 10-d FL-cultured BMCs. FCs and p-preDCs 
were also sorted from fresh BM. Cells were incubated for 18 h with medium 
or CpG ODN and then stained with the MHC–class II, CD80, CD86 FITC-
labeled, or isotype control antibodies. Data are means   SEM of FACS 
analysis of at least three experiments.P-PREDCS FACILITATE ALLOGENEIC HSC ENGRAFTMENT | Fugier-Vivier et al. 378
p-preDCs population (Fig. 7 A) and followed the kinetic of
engraftment. Notably, facilitation was significantly impaired
in recipients of HSCs   FCs without p-preDCs, with a sur-
vival mean of 29.3 d   2.22 (Fig. 7 B) compared with total
FCs (P   0.0006). In striking contrast, p-preDC FCs alone
facilitated HSC engraftment, but with less efficiency than the
total FC population. In that group, at 3 mo, all surviving re-
cipients of HSCs  p-preDC FCs exhibited high levels of
donor chimerism ( 95%) and multilineage production (un-
published data). These data definitively prove that p-preDCs
play the main role in the facilitating function but could not
replace total FCs.
DISCUSSION
HSC chimerism has the potential to induce tolerance to or-
gan transplants and restore self-tolerance for treatment of au-
toimmune diseases. However, the widespread application of
this promising therapy in the clinic is dependent upon re-
ducing the toxicity associated with conventional BMT. A
great deal of attention has been focused on identification of
cells with facilitating potential to enhance HSC engraftment
and avoid the toxicity of BMT. One such subpopulation is
graftment, but less efficiently than the FCs total. Donor-
derived hematopoietic cells were present at levels  95% in
all alive animals receiving HSCs   p-preDCs at 3 mo after
transplantation (Fig. 6 B), indicating that the chimerism was
significantly high and consistent between all recipients.
Multilineage production was present in animals trans-
planted with HSCs   p-preDCs at 3 mo after transplanta-
tion (Fig. 6 B).
To test whether the chimerism achieved with transplanta-
tion of HSCs   p-preDCs induced donor-specific tolerance,
skin grafts from B6 (HSC donor), and BALB/c (third-party)
mice were performed. Donor-specific skin grafts were ac-
cepted by chimeras (MST   90 d), whereas third-party
(BALB/c) grafts were promptly rejected (MST   13.5 d; Fig.
6 C). In conclusion, p-preDCs enhance engraftment of puri-
fied allogeneic HSCs, as shown by chimerism and tolerance to
donor antigens, but with somewhat less efficiency than FCs.
Depletion of p-preDCs FCs abrogates facilitation
To determine whether the p-preDCs in the FC population
were the critical subpopulation responsible for facilitating
function, we coinjected HSCs with FCs depleted of the
Figure 5. FL-mobilized FCs facilitate HSC engraftment in allogeneic 
recipients. (A) FACS analysis of subpopulations in sorted FL-mobilized 
FCs. CD8  /TCR   /TCR    FL-mobilized FCs were sorted and stained 
after FcR blocking. Four-color flow cytometry analysis was performed to 
characterize distinct subtypes. The CD11cdim and the CD11cbright populations 
were gated and further analyzed for the presence of CD11b and B220 
marker expression. The dot plots are representative of two independent 
experiments in each B6 and B10.BR mouse strain. (B) FL-mobilized FCs 
from PB facilitate engraftment of HSCs (B10.BR → B10). B10-recipient 
mice were conditioned with 950 cGy TBI and were given 5,000 HCs from 
untreated B10.BR donors either alone ( ) or mixed with 30,000 purified 
FCs from untreated B10.BR BM ( ) or from B10.BR FL-treated FCs from 
PB ( ). Survival was followed for up to 6 mo. (C) Donor multilineage 
typing of HSC   FL FC chimeras (B10.BR → B10). T cell (TCR ), NK cell 
(NK1.1), B cell (B220), macrophage (Mac-1), and granulocyte (Gr-1) markers 
were assessed on donor-derived (H-2Kk) PBL from recipient mice 3 mo after 
transplantation. Data are representative from one chimera out of four 
performed. (D) Survival of skin grafts in mixed allogeneic chimeras 
(B10.BR → B10). Donor-specific (B10.BR, n   5) and third-party (BALB/c, 
n   5) skin grafts were transplanted in mixed allogeneic chimeras 3 mo 
after HSC plus FL-mobilized PB FC transplantation. Data shows skin graft 
survival over 100 d.JEM VOL. 201, February 7, 2005 379
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the CD8 /TCR  FCs that enhance engraftment of purified
allogeneic HSCs without causing GVHD (8, 10). Until
now, the precise characterization of FCs has remained con-
troversial due to the heterogeneity of the CD8 /TCR 
population and the infrequency of the various components.
In the present studies, we demonstrate that the major com-
ponent of the FC population resembles p-preDCs, making
them likely candidates for the biologic function of facilita-
tion. We show for the first time that p-preDCs significantly
facilitate HSC engraftment in allogeneic recipients and in-
duce tolerance without causing GVHD.
Previously, the heterogeneous CD8 /TCR  FC popu-
lation was described as sharing phenotypic characteristics
with CD8  lymphoid DCs (8). At that time, the phenotype
for murine p-preDCs was unknown, making an assessment
of the relative contribution of this DC subset to facilitation
impossible. We have now demonstrated that the B220 /
CD11cdim/CD11b  cells in the FC gate exhibit a morphol-
ogy and a phenotype that closely resembles p-preDCs. Un-
like mouse BM p-preDCs, most of which are CD8  , all of
the B220 /CD11cdim/CD11b  FCs express the CD8  anti-
gen. CD8  expression on mouse p-preDCs has been dem-
onstrated to vary according to tissue source and state of acti-
vation, increasing from 10 to 30% on resting BM p-preDCs
to 70 to 100% after activation (24, 30, 34). We therefore hy-
pothesized that the B220 /CD11cdim/CD11b  FCs in the
BM represent resting BM CD8   p-preDCs. This hypothe-
sis is reinforced by the fact that isolated FCs from fresh/
untreated BM exhibit a low expression of costimulatory
molecules (i.e., MHC class II, CD80, CD86), CD40 (un-
published data), and no CD205 expression (unpublished
data), as has been reported for p-preDCs (24, 35). Although
other cells, including B cells, NK cells, granulocytes, and
monocytes are also present in the FC population, the paucity
of these cells in the functional FL-mobilized PB-FC popula-
tion (unpublished data) led us to conclude that these cells do
not play a significant role in facilitation and reinforces our
hypothesis that this recently described rare population of
p-preDCs are central to facilitation.
In the present studies, we have shown that FCs share
many features with p-preDCs, including their response to
CpG ODN with: (a) secretion of similar cytokines and che-
mokines; and (b) maturation. The hallmark of p-preDCs is
the capacity to produce high amounts of IFN-type I, con-
sisting of IFN- , and IFN- , in response to appropriate
stimulation (19, 23). Mouse p-preDCs, as their human
counterparts, respond preferentially to ligands for TLR7 and
TLR9 and only poorly to ligands for TLR2, TLR3, or
TLR4 (36). Notably, FCs produce IFN-  after stimulation
with CpG ODN, and none after stimulation with LPS
(TLR4 ligand; unpublished data). Besides IFN- , FCs pro-
duce other cytokines and chemokines, including MIP-1 ,
MCP-1, TNF- , RANTES, IL-6, IFN- , and IL-12p70.
p-preDCs are potently “tolerogeneic” under selected cir-
cumstances, and have been shown to induce anergy in an
antigen-specific CD4  T cell line (37), differentiation of
naive CD4 and CD8 T cells into Th2 cells (38), and induc-
tion of regulatory T cells in vitro (31, 39, 40). Moreover, a
recent publication has shown that the adoptive transfer of
Figure 6. p-preDCs facilitate HSC engraftment in mismatched 
recipients. (A) Survival of allogeneic recipients transplanted with HSCs and 
p-preDCs from BM (B6 → C3H). C3H-recipient mice were conditioned with 
950 cGy TBI and were given 5,000 HSCs either alone (HSC group,  ) or mixed 
with 30,000 purified FCs (HSC   FC group,  ), or with p-preDCs (CD11cdim/
CD11b /B220 /Lin ; HSC   p-preDC group,  ) from B6 mice. Some re-
cipient mice were used as irradiation controls (----). The cumulative survival 
percentage of recipients is represented by the Kaplan-Meier method, and 
animals were followed for 6 mo. *, P   0.0083 between the HSC   FC group 
and the HSC   p-preDC group; **, P   0.0076 between the HSC   p-preDC 
group and the HSC group. (B) Multilineage typing of HSC   p-preDC chi-
meras (B6 → C3H). T cell (TCR ), NK cell (NK1.1), B cell (B220), macrophage 
(Mac-1), and granulocyte (Gr-1) markers were assessed on donor-derived 
(H-2Kk) PBL from recipient mice 3 mo after transplantation. Data are repre-
sentative from one chimera of six performed. (C) Survival of skin grafts in 
HSC   p-preDC chimeras (B6 → C3H). Donor-specific (B6, n   8) and third-
party (BALB/c, n   8) skin grafts were performed 3 mo after HSC plus p-preDC 
transplantation. Data shows skin graft survival over 90 d.P-PREDCS FACILITATE ALLOGENEIC HSC ENGRAFTMENT | Fugier-Vivier et al. 380
p-preDCs prevented the development of asthma in a mouse
model outlining the tolerogenic capacity of p-preDCs (40).
In light of the similarities between preDCs and FCs, it is
possible that FCs induce immune deviation to promote a
tolerogeneic milieu for HSC engraftment either via cyto-
kines, suppression of effector CD8 T cells and/or generation
of regulatory T cells. The fact that FCs produce a significant
amount of IL-10, a potent antiinflammatory cytokine (41)
used to generate regulatory T cells in vitro or in vivo (42,
43), supports this hypothesis. The generation of regulatory T
cells after FC transplantation may enhance engraftment by
tolerizing alloreactive responses. Interestingly, FCs highly
up-regulate CD86 expression after CpG ODN stimulation.
It is therefore possible that after transplantation, the CD86
on FCs interacts with its ligand, CTLA-4, on T cells, leading
to a decrease in allogeneic T cell responses. Although outside
the scope of this manuscript, studies are in progress to deter-
mine whether FCs induce Th2 immune deviation and/or
the production of donor regulatory T cells.
In humans and in mice, the development of p-preDCs is
dependent upon FL (32). Similarly, FL is also a key cytokine
for FC generation and expansion, as evidenced by the FL-BM
cultures and the mobilization of FCs in PB (33). FCs propa-
gated from BMCs in vitro develop dendrites and up-regulation
of activation markers. FL treatment in vivo induces the matu-
ration of FCs. Approximately 20% of FL-FCs exhibit features
of mature lymphoid DCs (B220 /CD11cbright /CD11b ) that
express CD86 and 60% express a p-preDC phenotype. Nota-
bly purified FL-mobilized FCs facilitate HSC engraftment very
efficiently. The mobilization of FCs by FL could represent a
more efficient approach to recruit functional “facilitating” or
tolerogeneic cells for clinical application, especially when lim-
ited numbers of cells are available for transplantation.
To date, there has been only indirect evidence to dem-
onstrate a sustained tolerogenic effect for p-preDCs in vivo.
Although prolongation of solid organ allografts has been
demonstrated in mice treated with enriched p-preDCs graft,
sustained donor-specific tolerance has not been achieved
(44). Similarly, although GVHD was decreased in occur-
rence and severity in BMT recipients who had an increase in
p-preDCs in the donor marrow inoculum, a direct biologic
role remains to be defined (20, 22). We show for the first
time that p-preDCs exhibit a significant and durable graft-
enhancing ability for HSCs in mismatched recipients. Nota-
bly, p-preDCs significantly enhanced engraftment of HSCs
without causing GVHD. Moreover, recipients of p-preDCs
facilitated HSC transplants exhibited donor-specific toler-
ance to skin allografts. Therefore, the tolerogenic effect of
this cell population was maintained in vivo as it relates to es-
tablishing chimerism and tolerance. The fact that depletion
of the p-preDCs component from the FCs total results in
loss of facilitation confirms that p-preDCs are the primary
component in facilitation.
It is interesting that the total FC population exhibits a
significantly greater engraftment-enhancing effect on HSCs
than do p-preDCs. A number of hypotheses could explain
this observation. p-preDC–like cells in the FC gate may be
the rare, CD8   subpopulation of the p-preDCs found in
the BM, and only CD8   p-preDCs may be able to fully re-
place FCs in this functional biological assay. Moreover,
p-preDC FCs facilitate less efficiently than total FCs, point-
ing to a requirement for collaborative cells and/or signals in
the FC population. p-preDCs may also not be in an appro-
priately activated state. Given the heterogeneous nature of cells
in the FC gate, it is possible that another collaborative cell
population (i.e., NK cells) is required for optimal function of
Figure 7. p-preDCs are the key cell subtype in the FCs population. 
(A) Sort of p-preDC FCs and FCs without p-preDCs. From an FC gate 
(CD8 /TCR ), CD11c /B220  cells were isolated and represented the 
p-preDC FC. The FCs without p-preDCs are all cells from the FC gate re-
maining after removal of the CD11cdim/B220  cells. (B) Survival of allogeneic 
recipients transplanted with HSCs and FCs without p-preDCs or p-preDC 
FCs (B10.BR → B10). B10 mice were conditioned with 950 cGy TBI and 
given 5,000 HSCs alone (HSC group,  ) or in combination with 30,000 
purified FCs (HSC   FC group, – –), p-preDC FCs (HSC   p-preDC FC 
group, -   -), or FCs without p-preDCs from B10.BR mice ( ). Some 
recipient mice were used as irradiation controls (     ). The cumulative 
survival of recipients is represented by the Kaplan-Meier method. Animals 
were followed for 4 mo. *, P   0.0165 between the HSC   FC group and 
the HSC group; **, P   0.0006 between the HSC FC group and the 
HSC FC without p-preDCs group.
—— —
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p-preDCs. In support of this mechanism is the fact that acti-
vation of p-preDCs by NK cells has been reported in vitro
(45). It is also possible that p-preDC phenotype cells within
the FC gate are distinct from the bulk population of BM
p-preDCs (other than activation or known maturation sta-
tus). The fact that FCs produce IL-10, whereas p-preDCs do
not in humans or mice, would point to an additional collab-
orative cell or signal in the FC population. Studies are un-
derway to evaluate this mechanism.
In conclusion, CD8 /TCR  FCs will have a significant
impact for the clinical application of HSC-induced chimer-
ism since tolerance can be promoted, GVHD avoided, and
safe transplants allowed in mismatched recipients (10, 46,
47). Notably, we show for the first time a direct in vivo ef-
fect for p-preDCs in facilitating HSC engraftment and in-
ducing durable tolerance to transplanted grafts. The identifi-
cation of the cells in the FC gate, and the mechanism by
which they mediate a full facilitation of HSC engraftment,
will lead to novel cell-based therapeutic strategies to opti-
mize the composition of the graft in order to reduce the
morbidity of HSC transplants in mismatched recipients.
MATERIALS AND METHODS
Mice.  5–10-wk-old male B10.BR/SgSnJ (B10.BR, H-2k), C3H/HeJ
(C3H, H-2k), C57BL/10SnJ (B10, H-2b), BALB/c (H-2d), or C57BL/6J
(B6, H-2b) mice were purchased from Jackson ImmunoResearch Laborato-
ries. Rodents were maintained under pathogen-free conditions in the
animal care facility at the Institute for Cellular Therapeutics, according to
specific University of Louisville, Institutional Animal Care and Use Com-
mittee, and National Institutes of Health animal care guidelines.
Flt3-ligand treatment of mice.  Recombinant human FL (provided by
Amgen) was diluted in sterile, filtered, endotoxin-free water at a concentra-
tion of 100  g/ml. Donor B10.BR mice were subcutaneously injected
with 10  g of FL daily for 10 d. B10.BR control mice were injected with
saline only. At the end of the treatment, peripheral blood was harvested and
collected into heparinized tubes.
mAb and flow cytometry.  The following mAbs (all from BD Bio-
sciences, except those labeled with APC-Cy7 from eBioscience) were used.
To sort CD8 /TCR  FCs: anti-CD8  (53–6.7) PE labeled, anti-TCR  
chain (H57-597), and anti-TCR    chain (GL3) FITC labeled. To sort
B220 /CD11cdim/CD11b  p-preDCs: anti-CD11b (M1/70) APC labeled,
anti-CD45R/B220 (RA3-6B2) APC-Cy7 labeled, anti-CD11c (HL3) PE
labeled, and anti-TCR   chain (H57-597), anti-TCR    chain (GL3),
anti-CD14 (rmC5-3), anti-CD19 (1D3), anti-pan–NK cells (DX5), and
anti-NK1.1 (PK136), all FITC labeled. To sort p-preDCs in the FC popu-
lation (p-preDC FCs): anti-CD8  (53–6.7) PE labeled, anti-TCR   chain
(H57-597), anti-TCR    chain (GL3) FITC labeled, anti-CD45R/B220
(RA3-6B2) APC-Cy7 labeled, anti-CD11c (HL3) PE labeled. To sort
HSCs: anti-TCR   chain (H57-597), anti-TCR    chain (GL3), anti-Ly–
6G (Gr-1), anti-CD11b, Mac-1 (M1/70), anti-CD8  (53–6.7), and anti-
CD45R/B220 (RA3-6B2), all FITC labeled, anti-Ly–6A/E (Sca-1; E13-
161.7) PE labeled and anti–c-Kit (CD117; 2B8) APC labeled. Reanalysis of
sorted FCs: purified FCs were stained with anti-CD16/CD32 (Fc III/II re-
ceptors; 2.4G2), anti-CD11c (HL3), anti-CD4 (RM4-5) and anti-CD19
(1D3) all APC labeled, anti-CD45R/B220 (RA3-6B2) PerCP labeled, and
anti-pan–NK cells (DX5), anti-NK1.1 (PK136), anti-CD14 (rmC5-3), and
anti-Ly–6G (Gr-1) FITC labeled. To analyze the activation state: anti-
CD80 (B7-1; 16-10A1), anti-CD86 (B7-2; 16-10A1), and anti-I–Ab (A b;
AF6-120.1) FITC labeled. For PBL typing and multilineage chimerism:
anti-H–2Kb (AF6-88.5) PE or FITC labeled, anti-H–2Kk (36–7-5) PE or
FITC labeled, anti-TCR   chain (H57-597), anti-NK1.1 (PK136), anti-
Ly–6G (Gr-1), anti-CD11b, Mac-1 (M1/70), and anti-CD45R/B220
(RA3-6B2) all FITC labeled.
BMC preparation.  BMC preparations were performed as described pre-
viously (9). In brief, BMCs were obtained by flushing femurs and tibias
from mice with cold media 199 (GIBCO BRL) containing 30  g/ml Gen-
tamicin (GIBCO BRL; referred to hereafter as chimera media [CM]). After
washing with CM, the BMCs were resuspended to 100   106 cells/ml in
sterile cell sort media (CSM: Hank’s balanced salt solution without phenol
red, 2% heat-inactivated fetal calf serum, 2  g/ml Hepes buffer, and 30  g/
ml of Gentamicin [all from GIBCO BRL]).
Culture of BMCs with FL.  BMCs were resuspended at 106 cells/ml in
culture medium consisting of RPMI 1640 (GIBCO BRL), 10% FBS
(GIBCO BRL), 1 mM sodium pyruvate (GIBCO BRL), 10 mM Hepes
(GIBCO BRL), 2 mM L-glutamine (GIBCO BRL), 100 U/ml penicillin,
100  g/ml streptomycin (GIBCO BRL), and 10 5 M 2-mercaptoethanol
(Sigma-Aldrich), supplemented with human FL (100 ng/ml; gift from Am-
gen). After 5 d of culture, half of the medium was replaced by fresh cyto-
kine-supplemented culture medium according to a protocol described pre-
viously (28).
Cell sorting. HSCs, FCs, and p-preDCs were sorted as described previ-
ously (9, 28, 48). HSCs were sorted for Sca-1 /c-Kit /Lin  expression,
FCs were sorted for CD8  /TCR   /TCR    expression, and
p-preDCs were sorted for CD11cdim/CD11b /B220  expression. p-preDC
FCs were isolated for CD11c /B220  expression in the FCs (CD8 /
TCR ) gate and FCs without preDCs were sorted by excluding CD11c /
B220  cells from the FC gate as shown in Fig. 7 A. In brief, BMCs were in-
cubated with Ab on ice for 30 min, cells were washed twice in the CSM,
filtered, and resuspended to a final concentration of 2.5   106 cells/ml in
the CSM for cell sorting. The isolation of the cell populations was per-
formed on FACSVantage Flow Cytometers (Becton Dickinson). The pop-
ulations of interest were isolated from the live lymphoid gate, and after re-
analysis, only cells with a purity of  94% were used.
Phenotypic analysis of sorted FCs.  Sorted FCs isolated from fresh
BMCs or FL-mobilized peripheral blood, with a purity ranging from 94 to
98%, were incubated with Fc receptor block (anti-CD16/CD32) before
staining with lineage-specific markers, including anti-CD4, CD11c, B220,
NK1.1, DX5, CD14, Gr-1, and CD19. During reanalysis of sorted FCs,
 1% of contaminating T cells (TCR   FITC and TCR   FITC) were
detected, which therefore allowed the use of FITC-conjugated–specific
markers for further analysis. To validate the specificity of staining, we used
various conjugates of the same antibody, including CD11c, CD4, and
CD19 conjugated to FITC and APC, as well as B220 conjugated with
PerCP, APC, or FITC (unpublished data). To analyze the subtypes of DCs
in the sorted FC population, sorted FCs were blocked and stained
with CD11b FITC, CD11c APC and B220 PerCP mAb to determine
the presence of myeloid preDCs (CD11c /B220 /CD11b ), p-preDCs
(CD11cdim/B220 /CD11b ), the common precursor population for DCs
(CD11c /B220 /CD11b ), or mature lymphoid DCs (CD8  /CD11c /
CD11b /B220 ). The cells were washed twice in CSM and analyzed on a
FACSCalibur using Cell Quest Software (Becton Dickinson).
CpG oligodeoxynucleotides stimulation.  Sorted p-preDCs or FCs
were cultured for 18 h at 105 cells/200  l in 96-well round-bottom culture
plates in culture medium in the presence or absence of toll-like receptor
(TLR)-9 ligand, CpG ODN 1668 (TCCATGACGTTCCGATGCT;
GIBCO BRL Custom Primers) at 1  M, TLR4 ligand, LPS from Esche-
richia coli (Sigma-Aldrich) at 10  g/ml, as described previously (28). CpG or
LPS-treated or -untreated cells were subsequently assayed for: (a) the ex-
pression of DC activation/maturation cell surface markers by FACS; and (b)
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supernatant of these cultures were collected for analysis of the production of
different cytokines by ELISA.
Cytospins.  Cells (30,000 to 60,000) were centrifuged for 5 min at 300
rpm. The slides were air dried, fixed with methanol, and dried at room
temperature. Wright-Giemsa staining was performed using the kit Hema3
according to the manufacturer’s protocol (Fisher Scientific).
Transmission electron microscopy.  Cells were pelleted at 1,000 g,
fixed in situ as a pellet in 2.5% glutaraldehyde, and processed for transmis-
sion electron microscopy using standard methods. Sections of 70 nm were
cut with a Reichert Ultracert S mounted on copper grids and counter-
stained with uranyl-acetate (2%) and lead citrate. Observations were per-
formed using a Joel 100 cx electron microscope.
Cytokine production by ELISA.  In brief, the cell-free supernatants of
12, 18, or 24 h cultured cells (FCs or p-preDCs) with or without CpG ODN
or LPS were collected and kept frozen at –80 C. The amount of cytokine pro-
duced was determined by: (a) ELISA kits for mouse IFN-  (R&D Systems) and
mouse TNF-  (Biosource International); and (b) multiplex for MIP-1 
(CCL3), GM-CSF, MCP-1 (CCL2), RANTES (CCL5), IFN- , IL-1 , IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-9, and IL-13 on 18 h incubation superna-
tants from three different experiments performed by Linco Diagnostic Services.
Reconstitution of allogeneic recipients with HSCs from untreated
marrow and FL-mobilized FCs.  HSCs were sorted from untreated
B10.BR mice (H-2k). FCs (CD8 /TCR ) were sorted from PB of 10 d
FL-treated B10.BR mice, or from untreated B10.BR mice as controls. Re-
cipient B10 mice (H-2b) were treated with 950 cGy of total body irradia-
tion (TBI) using a 137-cesium source (Gamma-cell 40 Excutor; Nordion
International). 6 h after irradiation, 5,000 HSCs were transplanted either
alone or in combination with 30,000 FCs by lateral tail vein injection. FCs
and HSCs were mixed before transplantation. A control group of irradiated
mice was also established. The survival was plotted over time.
Reconstitution of allogeneic recipients with HSC   BM FCs,
p-preDCs, and FC subpopulations.  Recipient mice were given 950
cGy TBI. 6 h after irradiation, recipients were transplanted with 5,000 puri-
fied allogeneic HSCs with or without 30,000 FCs or p-preDCs resuspended
in CM, or 15,000 FCs depleted of p-preDCs or 15,000 p-preDC FCs via
lateral tail vein injection. A group of irradiated mice served as controls.
Graft survival was estimated by the Kaplan-Meier method.
Characterization of donor multilineage engraftment by flow cy-
tometry. Donor engraftment in the recipient was quantified by peripheral
blood cell typing using flow cytometry. Specifically, two-color flow was
used to determine the percentage of PBL that express H-2b or H-2k MHC
class I antigen as described previously (49). For multilineage analysis, PBL
were stained with donor-specific anti-H–2Kb–PE or anti-H–2Kk–PE mAb
along with a combination of the following Ab: anti–Gr-1, anti–Mac-1,
anti–  -TCR, anti-B220, anti-NK1.1, anti-CD11c, and anti-CD19. Cells
were washed, acquired, and analyzed on the FACSCalibur.
Skin grafts.  Skin grafts were performed by techniques published previ-
ously (50). In brief, full-thickness skin grafts from the tail of B10.BR, B10,
B6, or BALB/c mice were harvested. Full-thickness graft beds were pre-
pared on the lateral thoracic wall. Three skin grafts (syngeneic, donor, and
third-party) were placed on each animal. Each graft was separated from the
others by a skin bridge of at least 3 mm. Skin grafts were covered by a dou-
ble layer of petroleum gauze and a cast. The cast was removed after 7 d.
Grafts were scored daily for percent rejection. Rejection was defined as
complete when no residual viable graft could be detected.
Significance estimates.  Survival was estimated according to the Kaplan-
Meier method and tested with the log rank statistic using SPSS 12.0 for Win-
dows software. The cumulative survival estimates the percentage of mice
alive after a given amount of time. All graphs of transplanted mice represent
experimental animals from at least three separate days of sorting and trans-
plantation. For the other experiments, statistical significance was determined
by application of the Student’s t test; P   0.05 was considered significant.
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